Enanta Pharmaceuticals (NASDAQ:ENTA) Share Price Crosses Below Two Hundred Day Moving Average of $13.04

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $13.04 and traded as low as $12.78. Enanta Pharmaceuticals shares last traded at $13.45, with a volume of 78,288 shares changing hands.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. HC Wainwright cut their target price on Enanta Pharmaceuticals from $28.00 to $27.00 and set a “buy” rating on the stock in a research report on Tuesday, May 7th. StockNews.com raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 8th. Finally, JMP Securities cut their price objective on Enanta Pharmaceuticals from $23.00 to $22.00 and set a “market outperform” rating on the stock in a research report on Tuesday, May 7th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $19.00.

Enanta Pharmaceuticals Price Performance

The company has a market cap of $278.29 million, a price-to-earnings ratio of -2.11 and a beta of 0.60. The firm’s 50 day simple moving average is $12.73 and its 200-day simple moving average is $13.04.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, May 6th. The biotechnology company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($1.26) by ($0.21). Enanta Pharmaceuticals had a negative return on equity of 64.85% and a negative net margin of 180.76%. The business had revenue of $17.05 million for the quarter, compared to analyst estimates of $16.47 million. On average, analysts forecast that Enanta Pharmaceuticals, Inc. will post -5.95 EPS for the current year.

Insider Buying and Selling

In related news, insider Tara Lynn Kieffer sold 7,266 shares of the stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $12.33, for a total transaction of $89,589.78. Following the completion of the transaction, the insider now directly owns 32,341 shares of the company’s stock, valued at $398,764.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 13.64% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ENTA. Nisa Investment Advisors LLC increased its stake in shares of Enanta Pharmaceuticals by 417.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 2,281 shares in the last quarter. State Board of Administration of Florida Retirement System purchased a new position in Enanta Pharmaceuticals during the first quarter worth $118,000. Quest Partners LLC acquired a new position in shares of Enanta Pharmaceuticals in the fourth quarter worth $146,000. Diversified Trust Co purchased a new stake in shares of Enanta Pharmaceuticals in the fourth quarter valued at $159,000. Finally, Strs Ohio boosted its stake in shares of Enanta Pharmaceuticals by 20.6% during the fourth quarter. Strs Ohio now owns 18,700 shares of the biotechnology company’s stock valued at $175,000 after acquiring an additional 3,200 shares during the last quarter. 94.99% of the stock is owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.